Tamara Fountain

Insider activity · 24 months0 buys1 saleCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 1 saleApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (0 ops.)

—

▼ Sales (1 ops.)

€165k

Latest filing published 18 Jun 2026 for RxSight, Inc..

Filing timeline

BuySale

Tamara Fountain

Insider track record

Disclosed buys

Disclosed sells

Signal history

No signal scores available.

Tamara Fountain: trading record in brief

This profile gathers the share dealings of Tamara Fountain across 2 companies, led by RxSight, Inc. and Sight Sciences, Inc. In total, 11 filings cover trades dated from 8 January 2023 to 17 June 2026.

Every open-market trade on record is a sale: 1 sale worth €165k. Outside the open market, there are 10 share grants.

On 18 June 2026 came the latest disclosure, a share grant in RxSight, Inc. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.